Hannah Bainbridge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hannah Bainbridge has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Wetscherek
Joint Department of Physics The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust London UK
3 shared publications - Fiona McDonald
Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK
2 shared publications - Joshua N. Freedman
Elekta Limited Crawley United Kingdom
2 shared publications - Marc Kachelrieß
Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Heidelberg, Germany
2 shared publications - Martin O. Leach
Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy & Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
2 shared publications - Simeon Nill
The Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 38, 100948
Recommendations for contouring of gross tumour volume for locally advanced lung cancer using magnetic resonance imaging
- 15 March 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 38, 100948
Open AccessRecommendations for contouring of gross tumour volume for locally advanced lung cancer using magnetic resonance imaging
- Open Access
- 28 June 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 110, 108985
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
- 28 June 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 110, 108985
Open AccessEfficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
- Open Access
- 23 May 2019
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (11) , 115005
Synthetic 4D-CT of the thorax for treatment plan adaptation on MR-guided radiotherapy systems
MR-guided radiotherapy treatment planning utilises the high soft-tissue contrast of MRI to reduce uncertainty in delineation of the target and organs at risk. Replacing 4D-CT with MRI-derived synthetic 4D-CT would support treatment plan adaptation on hybrid MR-guided radiotherapy systems for inter- and intrafractional differences in anatomy and respiration, whilst mitigating the risk of CT to MRI registration errors. Three methods were devised to calculate synthetic 4D and midposition (time-weighted mean position of the respiratory cycle) CT from 4D-T1w and Dixon MRI. The first approach employed intensity-based segmentation of Dixon MRI for bulk-density assignment (sCTD). The second step added spine density information using an atlas of CT and Dixon MRI (sCTDS). The third iteration used a polynomial function relating Hounsfield units and normalised T1w image intensity to account for variable lung density (sCTDSL). Motion information in 4D-T1w MRI was applied to generate synthetic CT in midposition and in twenty respiratory phases. For six lung cancer patients, synthetic 4D-CT was validated against 4D-CT in midposition by comparison of Hounsfield units and dose-volume metrics. Dosimetric differences found by comparing sCTD,DS,DSL and CT were evaluated using a Wilcoxon signed-rank test (p = 0.05). Compared to sCTD and sCTDS, planning on sCTDSL significantly reduced absolute dosimetric differences in the planning target volume metrics to less than 98 cGy (1.7% of the prescribed dose) on average. When comparing sCTDSL and CT, average radiodensity differences were within 97 Hounsfield units and dosimetric differences were significant only for the planning target volume D99% metric. All methods produced clinically acceptable results for the organs at risk in accordance with the UK SABR consensus guidelines and the LungTech EORTC phase II trial. The overall good agreement between sCTDSL and CT demonstrates the feasibility of employing synthetic 4D-CT for plan adaptation on hybrid MR-guided radiotherapy systems.
- 23 May 2019
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (11) , 115005
Open AccessSynthetic 4D-CT of the thorax for treatment plan adaptation on MR-guided radiotherapy systems
MR-guided radiotherapy treatment planning utilises the high soft-tissue contrast of MRI to reduce uncertainty in delineation of the target and organs at risk. Replacing 4D-CT with MRI-derived synthetic 4D-CT would support treatment plan adaptation on hybrid MR-guided radiotherapy systems for inter- and intrafractional differences in anatomy and respiration, whilst mitigating the risk of CT to MRI registration errors. Three methods were devised to calculate synthetic 4D and midposition (time-weighted mean position of the respiratory cycle) CT from 4D-T1w and Dixon MRI. The first approach employed intensity-based segmentation of Dixon MRI for bulk-density assignment (sCTD). The second step added spine density information using an atlas of CT and Dixon MRI (sCTDS). The third iteration used a polynomial function relating Hounsfield units and normalised T1w image intensity to account for variable lung density (sCTDSL). Motion information in 4D-T1w MRI was applied to generate synthetic CT in midposition and in twenty respiratory phases. For six lung cancer patients, synthetic 4D-CT was validated against 4D-CT in midposition by comparison of Hounsfield units and dose-volume metrics. Dosimetric differences found by comparing sCTD,DS,DSL and CT were evaluated using a Wilcoxon signed-rank test (p = 0.05). Compared to sCTD and sCTDS, planning on sCTDSL significantly reduced absolute dosimetric differences in the planning target volume metrics to less than 98 cGy (1.7% of the prescribed dose) on average. When comparing sCTDSL and CT, average radiodensity differences were within 97 Hounsfield units and dosimetric differences were significant only for the planning target volume D99% metric. All methods produced clinically acceptable results for the organs at risk in accordance with the UK SABR consensus guidelines and the LungTech EORTC phase II trial. The overall good agreement between sCTDSL and CT demonstrates the feasibility of employing synthetic 4D-CT for plan adaptation on hybrid MR-guided radiotherapy systems.
- Open Access
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S526-S527
PO-0959: Dosimetric Evaluation of Midposition Pseudo-CT for MR-only Lung Radiotherapy Treatment planning
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S526-S527
Open AccessPO-0959: Dosimetric Evaluation of Midposition Pseudo-CT for MR-only Lung Radiotherapy Treatment planning